Free tool
FAERS Monitor: Lidoderm
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020612 or its brand name (Lidoderm, Lidocaine). Reports on generic versions are filed under their own applications.
Reports
57,026
Serious
40,998
72% of reports
Hospitalization
20,211
Death reported
5,778
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective4,078
- pain3,849
- nausea3,652
- fatigue3,632
- headache3,220
- off label use2,920
- dyspnoea2,617
- diarrhoea2,388
- pneumonia2,356
- vomiting2,220
- fall2,149
- dizziness2,087
- sinusitis2,059
- death2,013
- pyrexia1,846
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 307 |
| 2005 | 302 |
| 2006 | 422 |
| 2007 | 435 |
| 2008 | 539 |
| 2009 | 652 |
| 2010 | 886 |
| 2011 | 1,491 |
| 2012 | 1,671 |
| 2013 | 1,140 |
| 2014 | 1,548 |
| 2015 | 2,564 |
| 2016 | 4,104 |
| 2017 | 3,075 |
| 2018 | 3,825 |
| 2019 | 4,650 |
| 2020 | 5,794 |
| 2021 | 4,030 |
| 2022 | 3,737 |
| 2023 | 4,121 |
| 2024 | 4,117 |
| 2025 | 4,291 |
| 2026 | 3,321 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,997,133 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| sinusitisSignal | 2,059 | 7.5 | 7.2 | 11,498 |
| pneumoniaSignal | 2,356 | 2.7 | 2.6 | 2,533 |
| fallSignal | 2,149 | 2.4 | 2.3 | 1,753 |
| painSignal | 3,849 | 2.3 | 2.2 | 2,956 |
| pyrexia | 1,846 | 2.0 | 1.9 | 895 |
| headache | 3,220 | 1.9 | 1.8 | 1,404 |
| vomiting | 2,220 | 1.7 | 1.7 | 718 |
| fatigue | 3,632 | 1.7 | 1.7 | 1,141 |
| dyspnoea | 2,617 | 1.7 | 1.6 | 786 |
| nausea | 3,652 | 1.7 | 1.7 | 1,101 |
| dizziness | 2,087 | 1.5 | 1.5 | 409 |
| diarrhoea | 2,388 | 1.4 | 1.3 | 240 |
| off label use | 2,920 | 1.2 | 1.2 | 131 |
| drug ineffective | 4,078 | 1.1 | 1.1 | 76 |
| death | 2,013 | 0.9 | 0.8 | 47 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.